News

Amatuximab (MORAb-009) is a monoclonal antibody that binds mesothelin, a cell surface protein on pancreatic, mesothelioma and a subset of other types of tumor cells. Morphotek said that

Radie, most recently, served as president and CEO of TransMolecular, a biotechnology company developing new cancer diagnostic and treatment products. Previously, Radie was chief business officer at Prestwick

The panel was convened as a part of the National Coverage Analysis (NCA) that was initiated by the Centers for Medicare and Medicaid Services (CMS). Dendreon claimed that

Provid claimed that this new, highly selective small molecule, PV-267, is designed to block a critical step in the autoimmune process of MS, which leads to the destruction

The Phase II study is expected to investigate the efficacy, safety and tolerability of Cogane administered for 28 weeks to approximately 400 patients with early stage Parkinson’s disease.

As per the terms of the agreement, Kwang Dong will develop and commercialise Tarafenacin in South Korea. Additionally, the terms of the agreement include an upfront payment and

Amylin and Lilly said that in the study, Byetta was associated with a lower incidence of CVD-related events than insulin, thiazolidinediones (TZDs) and sulfonylureas and a comparable incidence

Merck Research Laboratories clinical research director Elizabeth Garner said that they were pleased with the outcome of the meeting and look forward to continued discussions with the FDA

PerformRx will help the California Department of General Services provide efficient pharmacy benefit management services to portions of the state’s population covered by DGS’s statewide pharmaceutical program. As